…at baseline and at one year were the most robust prognostic factors of long-term outcomes (Chung et al. Ann Neurol 2020;87:63-74). Results at 20 years were previously published as Fisniku et al. Brain 2008;131:808-817. The prospective study enrolled 132 CIS patients at two centres during the period 1984-1987. For the present analysis, subjects were classified as CIS or MS (McDonald 2010 criteria); MS patients were further classified as RRMS or SPM…
…Forum (www.alzforum.org/news/conference-coverage/exposure-exposure-exposure-ctad-aducanumab-scientists-make-case). The median cumulative aducanumab exposure was 116 mg/kg for patients enrolled prior to the protocol amendment compared to 153 mg/kg for those enrolled afterward (31% increase). Overall, 29% of patients in EMERGE and 22% of patients in ENGAGE received the maximum treatment exposure (10 mg/kg over 78 weeks). For the subgroup analysis, t…
…currently in review by Health Canada. The S-enantiomer of ketamine is a non-competitive glutamate N-methyl-D-Aspartate (NMDA) receptor antagonist and is administered intranasally. Medical supervision is required during dosing due to the risks of sedation and dissociation. The efficacy of esketamine appears to be somewhat modest – it met its primary endpoint in only one of three trials – but addresses a need for more options in managing TRD. At pre…
…r speculated that increasing gastric pH with PPIs may reduce vitamin B12 absorption. A review earlier this also raised concerns about the widespread use of PPIs, which are available over-the-counter in many countries, and the possible neurological sequelae associated with chronic PPI use (Novotny et al. Front Neurol 2019;9:1142)….
…You are now leaving the NeuroSens website (www.neuro-sens.com). Lind Publishing Inc. accepts no responsibility for the content of linked sites. Click here if you wish to continue….
